Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence

2018 ◽  
Vol 21 (1) ◽  
pp. e13020 ◽  
Author(s):  
Eva M. Teegen ◽  
Michael Dürr ◽  
Max M. Maurer ◽  
Franziska Eurich ◽  
Antonia Vollbort ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Kidney Function ◽  
Antiviral Treatment ◽  
Direct Acting Antivirals ◽  
Transplant Patients ◽  
Direct Acting

scholarly journals Direct‐acting antivirals ability to clear intestinal HCV‐RNA in liver transplant patients

2020 ◽  
Vol 22 (5) ◽  
Author(s):  
Giada Pietrosi ◽  
Giovanna Russelli ◽  
Floriana Barbera ◽  
Gabriele Curcio ◽  
Fabio Tuzzolino ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Hcv Rna ◽  
Direct Acting Antivirals ◽  
Transplant Patients ◽  
Direct Acting

Optimal therapy in hepatitis C virus liver transplant patients with direct acting antivirals

2014 ◽  
Vol 35 ◽  
pp. 44-50 ◽  
Author(s):  
Audrey Coilly ◽  
Bruno Roche ◽  
Jean-Charles Duclos-Vallée ◽  
Didier Samuel
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Liver Transplant ◽  
Direct Acting Antivirals ◽  
Optimal Therapy ◽  
Transplant Patients ◽  
Direct Acting

Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral loads, allograft function and morphology

2006 ◽  
Vol 26 (7) ◽  
pp. 811-816 ◽  
Author(s):  
Arno Kornberg ◽  
Bernadett Kupper ◽  
Andrea Tannapfel ◽  
Katharina Thrum ◽  
Erik Barthel ◽  
...  
Keyword(s):  
Liver Transplant ◽  
Antiviral Treatment ◽  
Treatment Withdrawal ◽  
Viral Loads ◽  
Transplant Patients ◽  
Allograft Function

Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States

Hepatology ◽  
2017 ◽  
Vol 66 (1) ◽  
pp. 46-56 ◽  
Author(s):  
Aijaz Ahmed ◽  
Stevan A. Gonzalez ◽  
George Cholankeril ◽  
Ryan B. Perumpail ◽  
Justin McGinnis ◽  
...  
Keyword(s):  
United States ◽  
Liver Transplant ◽  
Effective Treatment ◽  
Treatment Strategy ◽  
Cost Effective ◽  
The United States ◽  
Direct Acting Antivirals ◽  
Cost Effective Treatment ◽  
Direct Acting

Direct-acting antiviral treatment for hepatitis C in liver transplant candidates and recipients

2017 ◽  
Vol 6 (S3) ◽  
pp. S598-S602
Author(s):  
Nobuhisa Akamatsu ◽  
Junichi Togashi ◽  
Kiyoshi Hasegawa ◽  
Norihiro Kokudo
Keyword(s):  
Hepatitis C ◽  
Liver Transplant ◽  
Antiviral Treatment ◽  
Direct Acting Antiviral ◽  
Transplant Candidates ◽  
Direct Acting

scholarly journals French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Cécile Brouard ◽  
Josiane Pillonel ◽  
Marjorie Boussac ◽  
Victor de Lédinghen ◽  
Antoine Rachas ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Antiviral Treatment ◽  
Hcv Infection ◽  
World Health ◽  
Direct Acting Antivirals ◽  
Substantial Impact ◽  
Chronic Hcv Infection ◽  
Chronic Hcv ◽  
Direct Acting ◽  
The Impact

Abstract Background Hepatitis C virus (HCV) elimination by 2030, as targeted by the World Health Organization (WHO), requires that 90% of people with chronic infection be diagnosed and 80% treated. We estimated the cascade of care (CoC) for chronic HCV infection in mainland France in 2011 and 2016, before and after the introduction of direct-acting antivirals (DAAs). Methods The numbers of people (1) with chronic HCV infection, (2) aware of their infection, (3) receiving care for HCV and (4) on antiviral treatment, were estimated for 2011 and 2016. Estimates for 1) and 2) were based on modelling studies for 2011 and on a virological sub-study nested in a national cross-sectional survey among the general population for 2016. Estimates for 3) and 4) were made using the National Health Data System. Results Between 2011 and 2016, the number of people with chronic HCV infection decreased by 31%, from 192,700 (95% Credibility interval: 150,900-246,100) to 133,500 (95% Confidence interval: 56,900-312,600). The proportion of people aware of their infection rose from 57.7 to 80.6%. The number of people receiving care for HCV increased by 22.5% (representing 25.7% of those infected in 2016), while the number of people on treatment increased by 24.6% (representing 12.1% of those infected in 2016). Conclusions This study suggests that DAAs substantially impact CoC. However, access to care and treatment for infected people remained insufficient in 2016. Updating CoC estimates will help to assess the impact of new measures implemented since 2016 as part of the goal to eliminate HCV.

scholarly journals Frequency of Potential Drug–Drug Interactions in the Changing Field of HCV Therapy

2020 ◽  
Vol 7 (2) ◽  
Author(s):  
Benjamin Schulte ◽  
Maximilian Wübbolding ◽  
Fiona Marra ◽  
Kerstin Port ◽  
Michael P Manns ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Real World ◽  
Ph Value ◽  
Antiviral Treatment ◽  
Patient Characteristics ◽  
Direct Acting Antivirals ◽  
Limited Data ◽  
Significant Challenge ◽  
Hcv Therapy ◽  
Direct Acting

Abstract Background With the introduction of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, drug–drug interactions (DDIs) emerged as significant challenge. Since then, HCV therapy and the infected population have rapidly changed. So far, very limited data are available regarding the clinical relevance of DDIs when using most modern DAA regimens. We aimed to assess how the importance of DDIs has evolved over time. Methods From January 2014 to July 2018, 668 consecutive HCV patients were evaluated for their outpatient medication and assessed for DDIs with DAAs. Different time periods were defined based on market approval of key DAAs: A (01/2014–11/2014), B (11/2014–08/2016), and C (08/2016–07/2018). Results The frequency of patients with real-world DDIs was highest in period B (A: 37.1%, B: 49.6%, C: 38.8%). The recently approved DAAs (period C) theoretically showed a lower DDI risk profile. However, real-world DDIs were still comparable to period A, as HCV patients’ characteristics changed (eg, age ≥75 years: A: 3.1%, B: 9.8%, C: 5.6%; polypharmacy/patients with ≥8 drugs: A: 11.1%, B: 15.2%, C: 17.2%). Furthermore, although DDIs via CYP 3A4 became less important for some modern regimens, other mechanisms like an altered pH value in the stomach, causing reduced bioavailability, evolved. Relevant DDIs most frequently occurred with proton pump inhibitors, metamizole, statins, and carvedilol. Conclusions DDIs during antiviral treatment still affect about 40% of HCV patients. The lower DDI potential of modern DAA regimens is partly counteracted by changing patient characteristics. Therefore, DDIs should not be underestimated.

Sign in / Sign up

Export Citation Format

Share Document